Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000667011
Ethics application status
Approved
Date submitted
3/08/2010
Date registered
16/08/2010
Date last updated
8/02/2016
Type of registration
Prospectively registered
Titles & IDs
Public title
Evaluation of antioxidant therapy in presbycusis: results of a prospective, randomized, double-blind and controlled clinical trial.
Query!
Scientific title
"Evaluation of antioxidant therapy on hearing improvement in presbycusis patients 60 and older: results of a prospective, randomized, double-blind and controlled clinical trial"
Query!
Secondary ID [1]
252359
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
presbycusis
257872
0
Query!
Condition category
Condition code
Alternative and Complementary Medicine
258032
258032
0
0
Query!
Other alternative and complementary medicine
Query!
Ear
258091
258091
0
0
Query!
Other ear disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
There are four treatment groups. Group 1: ginkgo biloba, Group 2: alpha lipoic acid with vitamin C, Group 3: papaverine hydrochloride with vitamin E, and Group 4 (Comparator): starch pill. Dry extract of ginkgo biloba 120 mg once a day, oral tablet taken daily for a total of 6 months, alpha lipoic acid 60 mg in combination with vitamin C 600 mg once a day, oral tablet taken daily for a total of 6 months, and vitamin E 400 mg combined with papaverine hydrochloride 100 mg once a day, oral tablet taken daily for a total of 6 months.
Query!
Intervention code [1]
256922
0
Treatment: Other
Query!
Comparator / control treatment
starch pill 100 mg once a day, oral tablet taken daily for a total of 6 months
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
258881
0
Primary Outcome: hearing improvement in an audiometric test
Query!
Assessment method [1]
258881
0
Query!
Timepoint [1]
258881
0
Timepoint: at 6 months after intervention commencement
Query!
Secondary outcome [1]
265032
0
Efects on tinnitus
Query!
Assessment method [1]
265032
0
Query!
Timepoint [1]
265032
0
nil
Query!
Eligibility
Key inclusion criteria
Adults with diagnosis of presbycusis by hearing tests and clinical evaluation.
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Will be excluded individuals with other causes for hearing loss, known allergy to any substances in question or with medical contraindications to using them. Patients taking anticoagulants or with coagulation disorders and diabetics will also be excluded from the sample.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
120 volunteers numbered containers will be randomly assigned to four different groups:30 individuals will take dry extract of Ginkgo biloba, 30 a-lipoic acid in combination with vitamin C, 30 papaverine hydrochloride in combination with vitamin E and 30 placebo.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Volunteers will be randomised by using a randomisation table created by computer software.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
23/08/2010
Query!
Actual
23/08/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
13/12/2010
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
120
Query!
Recruitment outside Australia
Country [1]
2796
0
Brazil
Query!
State/province [1]
2796
0
Sao Paulo
Query!
Funding & Sponsors
Funding source category [1]
257375
0
Other Collaborative groups
Query!
Name [1]
257375
0
CDA - Centro do Deficiente Auditivo
Query!
Address [1]
257375
0
Borges Lagoa street, 783 2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo Sao Paulo - Brazil
Query!
Country [1]
257375
0
Brazil
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
CDA
Query!
Address
Borges Lagoa streeet, 783 – 2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo – Sao Paulo - Brazil
Query!
Country
Brazil
Query!
Secondary sponsor category [1]
256611
0
None
Query!
Name [1]
256611
0
nil
Query!
Address [1]
256611
0
nil
Query!
Country [1]
256611
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
259392
0
Ethics Committee of the Federal University of Sao Paulo / Hospital Sao Paulo
Query!
Ethics committee address [1]
259392
0
Botucatu street, 572-1 st. floor - room 14 cep 04023-062 - Sao Paulo / Brazil
Query!
Ethics committee country [1]
259392
0
Brazil
Query!
Date submitted for ethics approval [1]
259392
0
Query!
Approval date [1]
259392
0
02/07/2010
Query!
Ethics approval number [1]
259392
0
CEP 0723/10
Query!
Summary
Brief summary
The study aimed to evaluate the efficacy of treatment with anti-oxidants in presbycusis, or deafness in the elderly. For this, the volunteers will be divided into four groups and each group will receive one of the following medications: ginkgo biloba, alpha lipoic acid + vitamin C, vitamin E + papaverine and placebo. After six months the hearing will be tested and compared with an initial test to check for hearing improvement with any of these therapies.
Query!
Trial website
Query!
Trial related presentations / publications
Evaluation of antioxidant treatment in presbyacusis: prospective, placebo-controlled, double-blind, randomised trial. Polanski JF, Cruz OL. J Laryngol Otol. 2013 Feb;127(2):134-41. doi: 10.1017/S0022215112003118.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
31458
0
Dr Jose Fernando Polanski
Query!
Address
31458
0
Rua Borges Lagoa, 783
Vila Clementino
ZIp code 04038-031
Sao Paulo-SP
Brasil
Query!
Country
31458
0
Brazil
Query!
Phone
31458
0
55 11 5576 4848 add 2427
Query!
Fax
31458
0
Query!
Email
31458
0
[email protected]
Query!
Contact person for public queries
Name
14705
0
Jose Fernando Polanski
Query!
Address
14705
0
Borges Lagoa street, 783 – 2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo – Sao Paulo
Query!
Country
14705
0
Brazil
Query!
Phone
14705
0
+55 41 99749470
Query!
Fax
14705
0
nil
Query!
Email
14705
0
[email protected]
Query!
Contact person for scientific queries
Name
5633
0
Jose Fernando Polanski
Query!
Address
5633
0
Borges Lagoa street, 783 – 2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo – Sao Paulo
Query!
Country
5633
0
Brazil
Query!
Phone
5633
0
+55 11 99749470
Query!
Fax
5633
0
Query!
Email
5633
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF